Fasenra vs Nucala
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Fasenra | US Nucala |
|---|---|---|
| Generic name | benralizumab Unverified catalogue summary (Generic name) for Fasenra in US; not checked against current local product information. | mepolizumab Unverified catalogue summary (Generic name) for Nucala in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Fasenra in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Nucala in US; not checked against current local product information. |
| Treats | Severe eosinophilic asthma Unverified catalogue summary (Treats) for Fasenra in US; not checked against current local product information. | Severe eosinophilic asthma, COPD, nasal polyps Unverified catalogue summary (Treats) for Nucala in US; not checked against current local product information. |
| Category | Respiratory Unverified catalogue summary (Category) for Fasenra in US; not checked against current local product information. | Respiratory Unverified catalogue summary (Category) for Nucala in US; not checked against current local product information. |
| Manufacturer | AstraZeneca Unverified catalogue summary (Manufacturer) for Fasenra in US; not checked against current local product information. | GSK Unverified catalogue summary (Manufacturer) for Nucala in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Fasenra in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Nucala in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Fasenra in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Nucala in US; not checked against current local product information. |
| Est. TV ad spend | $80M | $75M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Fasenra in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Nucala in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Fasenra or Nucala better?
This directory does not compare clinical effectiveness or safety. Listing Fasenra and Nucala together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Fasenra and Nucala?
The table shows catalogue identification and estimated advertising information for Fasenra and Nucala, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Fasenra has the larger estimated TV advertising budget of the two.